Literature DB >> 8650489

Ethiologic treatment of acute and chronic Chagas' Disease [corrected].

A A Fragata Filho1, M A da Silva, E Boainain.   

Abstract

The uncertainties in the ethiological treatment of Chagas' Disease are consequence of the lack of entire knowledge of its pathogeny and the no existence of a healing criterium. There is a consensus that antiparasite drugs should be in the acute phase of the infection, regardless of the infection route, in new crisis, in patients under immunosuppression and in organs transplantation. There is still controversy regarding subacute, chronic or indetermined phase or cases with mild cardia/digestive forms, not included in the situations listed above neither in a research protocol. The treatment includes oral benzonidazol 5 mg/kg/dat, bid or tid for 60 days. In 71 patients monitored in this fashion, the authors have found 60% of negative xenodiagnostic at the end of treatment It is still necessary, however, to continue to investigate and accomplishing more randomized trials to confirm the efficacy of such method, and also to try to obtain effective and less toxic agents. It is also fundamental to standardize a more reliable healing criterium.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8650489     DOI: 10.1590/s1516-31801995000200020

Source DB:  PubMed          Journal:  Sao Paulo Med J        ISSN: 1516-3180            Impact factor:   1.044


  10 in total

1.  Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment.

Authors:  Vera Lucia Pereira-Chioccola; Abilio Augusto Fragata-Filho; Antonio Marcos de Apparecida Levy; Mauricio M Rodrigues; Sergio Schenkman
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Authors:  Susana A Laucella; Damián Pérez Mazliah; Graciela Bertocchi; María G Alvarez; Gretchen Cooley; Rodolfo Viotti; María C Albareda; Bruno Lococo; Miriam Postan; Alejandro Armenti; Rick L Tarleton
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

Review 3.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

4.  Vismione B Interferes with Trypanosoma cruzi Infection of Vero Cells and Human Stem Cell-Derived Cardiomyocytes.

Authors:  Gabriele Sass; Armelle T Tsamo; Gwladys A M Chounda; Pamela K Nangmo; Nazish Sayed; Adriana Bozzi; Joseph C Wu; Augustin E Nkengfack; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

5.  A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention.

Authors:  Girley Francisco Machado-de-Assis; Glaucia Alessio Diniz; Roberto Araújo Montoya; João Carlos Pinto Dias; José Rodrigues Coura; George Luiz Lins Machado-Coelho; Pedro Albajar-Viñas; Rosália Morais Torres; Marta de Lana
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

6.  A Combination of Itraconazole and Amiodarone Is Highly Effective against Trypanosoma cruzi Infection of Human Stem Cell-Derived Cardiomyocytes.

Authors:  Gabriele Sass; Roy T Madigan; Lydia-Marie Joubert; Adriana Bozzi; Nazish Sayed; Joseph C Wu; David A Stevens
Journal:  Am J Trop Med Hyg       Date:  2019-08       Impact factor: 2.345

7.  Screening of Potential anti-Trypanosoma cruzi Candidates: In Vitro and In Vivo Studies.

Authors:  Maria de Nazaré C Soeiro; Solange Lisboa de Castro
Journal:  Open Med Chem J       Date:  2011-03-09

8.  Therapy of chagas disease: implications for levels of prevention.

Authors:  Sergio Sosa-Estani; Lisandro Colantonio; Elsa Leonor Segura
Journal:  J Trop Med       Date:  2012-03-05

9.  Longitudinal follow up of serological response in children treated for Chagas disease.

Authors:  Guillermo Moscatelli; Samanta Moroni; Facundo García Bournissen; Nicolás González; Griselda Ballering; Alejandro Schijman; Ricardo Corral; Margarita Bisio; Héctor Freilij; Jaime Altcheh
Journal:  PLoS Negl Trop Dis       Date:  2019-08-29

10.  Immunopathological aspects of experimental Trypanosoma cruzi reinfections.

Authors:  Juliana Reis Machado; Marcos Vinícius Silva; Diego Costa Borges; Crislaine Aparecida da Silva; Luis Eduardo Ramirez; Marlene Antônia dos Reis; Lúcio Roberto Castellano; Virmondes Rodrigues; Denise Bertulucci Rocha Rodrigues
Journal:  Biomed Res Int       Date:  2014-06-24       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.